SONX

NYSE

Sonendo Inc.

SectorHealth CareIndustryMedical/Dental InstrumentsIPO2021

News25/Ratings6

Sonendo, Inc. develops, manufactures, and sells devices for root canal therapy in the United States and Canada. It offers GentleWave, a device to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The company also offers SoundSeal, a material used to build and create a sealing platform on the top of the crown; and Sonendo-branded liquid solution of ethylenediaminetetraacetic acid used to help debride and disinfect the root canal system. In addition, it provides The Digital Office, a practice management software. The company was formerly known as Dentatek Corporation and changed its name to Sonendo, Inc. in March 2011. Sonendo, Inc. was incorporated in 2006 and is based in Laguna Hills, California.

News · 26 weeks10%

2025-10-262026-04-19

Mix190d

Other1(100%)

Latest news

25 items

71dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Sonendo Inc.
SCHEDULE 13G/A - Sonendo, Inc. (0001407973) (Subject)
246dPR
Sonendo Strengthens Leadership Team With Promotion of John McGaugh to Chief Operating Officer
Sonendo, Inc. ("Sonendo" or the "Company") (OTC:SONX), a leading dental technology company and developer of the GentleWave® System, today announced the promotion of John McGaugh to Chief Operating Officer. Mr. McGaugh previously held the position of Senior Vice President of Operations. "Since Sonendo embarked on its strategic reset in early-2024, the Company has stabilized revenue, generated significant leverage in gross margin, and meaningfully lowered total operating expenses, adjusted EBITDA loss and cash burn," stated Bjarne Bergheim, President and Chief Executive Officer of Sonendo. "John has been a significant contributor to all those improvements, and we expect he will continue to
253dPR
Sonendo, Inc. Reports Second Quarter 2025 Financial Results and Reaffirms Financial Guidance
Sonendo, Inc. ("Sonendo" or the "Company"), a leading dental technology company and developer of the GentleWave® System, today reported select financial results for the three-months ended June 30, 2025 and reaffirmed 2025 financial guidance. Select Second Quarter Financial Results Generated $7.4 million of total revenue for the second quarter of 2025, an 11% decline compared to the prior year period, which was expected and driven entirely by lower console sales through a smaller and more cost effective sales team; Reported an increase in gross margin to 41% for the second quarter of 2025, up 320 basis points compared to the prior year period; Reported a $3.6 million reduction in
323dPR
Sonendo, Inc. Reports First Quarter 2025 Financial Results and Issues Financial Guidance
Sonendo, Inc. ("Sonendo" or the "Company") (OTC:SONX), a leading dental technology company and developer of the GentleWave® System, today reported select financial results for the first quarter ended March 31, 2025 and issued short and long-term financial guidance. Recent Highlights Generated $7.4 million of total revenue for the first quarter of 2025, representing 5% growth compared to the prior year period; Drove a substantial increase in gross margin to 44% for the first quarter of 2025, up 1600 basis points compared to the 28% gross margin for the prior year period; Reported a 48% year-over-year improvement in Adjusted EBITDA loss to $3.9 million for the first quarter of 2025
346dSEC
SEC Form D filed by Sonendo Inc.
D - Sonendo, Inc. (0001407973) (Filer)
357dPR
Sonendo, Inc. Announces $5.0 Million Private Placement
Sonendo, Inc. (OTC:SONX) ("Sonendo" or the "Company"), a leading dental technology company and developer of the GentleWave® System, today announced a private placement of common stock, resulting in gross proceeds of $5.0 million (the "Private Placement"). New and existing investors, including certain directors and officers of the Company, participated in the financing. Sonendo intends to use the proceeds from the financing to expand commercial programs to drive revenue growth, continue executing ongoing business restructuring activities to further reduce operating expenses and accelerate the path to positive adjusted EBITDA and operating cash flow, to retain senior leadership and key emplo
393dSEC
SEC Form 10-K filed by Sonendo Inc.
10-K - Sonendo, Inc. (0001407973) (Filer)
393dPR
Sonendo Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
Sonendo, Inc. (OTC:SONX) ("Sonendo" or the "Company"), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the quarter and year ended December 31, 2024. Quarterly Highlights Generated $8.3 million total revenue for the fourth quarter 2024; Drove substantial 1,570 and 1,260 basis points of GAAP and adjusted (non-GAAP) gross margin expansion for the fourth quarter 2024 to 41.1% and 41.3%, respectively, as compared to the prior year quarter; Significantly reduced GAAP operating loss to $5.6 million and adjusted EBITDA (non-GAAP) loss to $4.7 million for the fourth quarter 2024, an improvement of 45.2% and 45.0%, respectively,
420dSEC
SEC Form EFFECT filed by Sonendo Inc.
EFFECT - Sonendo, Inc. (0001407973) (Filer)
420dSEC
SEC Form EFFECT filed by Sonendo Inc.
EFFECT - Sonendo, Inc. (0001407973) (Filer)
421dSEC
SEC Form S-8 POS filed by Sonendo Inc.
S-8 POS - Sonendo, Inc. (0001407973) (Filer)
421dSEC
SEC Form S-8 POS filed by Sonendo Inc.
S-8 POS - Sonendo, Inc. (0001407973) (Filer)
421dSEC
SEC Form S-8 POS filed by Sonendo Inc.
S-8 POS - Sonendo, Inc. (0001407973) (Filer)
421dSEC
SEC Form S-8 POS filed by Sonendo Inc.
S-8 POS - Sonendo, Inc. (0001407973) (Filer)
421dSEC
SEC Form S-8 POS filed by Sonendo Inc.
S-8 POS - Sonendo, Inc. (0001407973) (Filer)
421dSEC
SEC Form S-8 POS filed by Sonendo Inc.
S-8 POS - Sonendo, Inc. (0001407973) (Filer)
421dSEC
SEC Form POS AM filed by Sonendo Inc.
POS AM - Sonendo, Inc. (0001407973) (Filer)
421dSEC
SEC Form POS AM filed by Sonendo Inc.
POS AM - Sonendo, Inc. (0001407973) (Filer)
434dSEC
SEC Form SCHEDULE 13G filed by Sonendo Inc.
SCHEDULE 13G - Sonendo, Inc. (0001407973) (Subject)
525d13D/G
Amendment: SEC Form SC 13G/A filed by Sonendo Inc.
SC 13G/A - Sonendo, Inc. (0001407973) (Subject)
525d13D/G
SEC Form SC 13G filed by Sonendo Inc.
SC 13G - Sonendo, Inc. (0001407973) (Subject)
527dSEC
SEC Form 10-Q filed by Sonendo Inc.
10-Q - Sonendo, Inc. (0001407973) (Filer)
527dSEC
Sonendo Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Sonendo, Inc. (0001407973) (Filer)
527dPR
Sonendo, Inc. Reports Third Quarter 2024 Financial Results
Sonendo, Inc. ("Sonendo" or the "Company") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Generated $8.0 million total revenue for the third quarter of 2024 and carried over a double-digit console backlog for the third straight quarter; Drove substantial increases in GAAP gross margin and adjusted gross margins (non-GAAP) to 41.2% and 42.6%, respectively, based primarily on lower manufacturing and console warranty costs; Significantly reduced GAAP operating loss to $7.5 million and adjusted EBITDA (non-GAAP) loss to $5.1 million, a 57% and
528dPR
Sonendo, Inc. to Release Third Quarter 2024 Financial Results and Postpone Conference Call on November 12, 2024
Sonendo, Inc. ("Sonendo") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today announced that management will postpone the third quarter 2024 conference call that was previously scheduled for after the market close on Tuesday, November 12th, 2024. The Company still intends to file its audited financial results on November 12th, 2024, but has postponed, until further notice, the accompanying conference call. Management will provide commentary on events subsequent to the end of the quarter ending September 30th, 2024, at a later date. About Sonendo Sonendo is a commercial-stage medical technology Company focused on saving teeth from tooth deca